

# Leyre Zubiri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9205063/publications.pdf>

Version: 2024-02-01

50  
papers

3,066  
citations

516710  
16  
h-index

377865  
34  
g-index

51  
all docs

51  
docs citations

51  
times ranked

6240  
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence and Predictors of CKD and Estimated GFR Decline in Patients Receiving Immune Checkpoint Inhibitors. American Journal of Kidney Diseases, 2022, 79, 134-137.	1.9	20
2	Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. Journal of Clinical Oncology, 2022, 40, 12-23.	1.6	75
3	Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer. Cancer Cell, 2022, 40, 103-108.e2.	16.8	30
4	Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy. JAMA Dermatology, 2022, 158, 189.	4.1	60
5	Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors. European Journal of Cancer, 2022, 163, 108-118.	2.8	21
6	Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19. Blood Cancer Discovery, 2022, 3, 181-193.	5.0	12
7	Case Report: Fulminant Celiac Disease With Combination Immune Checkpoint Therapy. Frontiers in Immunology, 2022, 13, 871452.	4.8	8
8	Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study. , 2022, 10, e004670.		21
9	Single-cell profiling of human heart and blood in immune checkpoint inhibitor-associated myocarditis.. Journal of Clinical Oncology, 2022, 40, 2507-2507.	1.6	1
10	Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting. Oncologist, 2021, 26, 49-55.	3.7	18
11	Liver biopsy findings in patients on immune checkpoint inhibitors. Modern Pathology, 2021, 34, 426-437.	5.5	48
12	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
13	Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors. Immunotherapy Advances, 2021, 1, 1tab014.	3.0	10
14	Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety Analysis. Journal of Vascular and Interventional Radiology, 2021, 32, 187-195.	0.5	17
15	Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. , 2021, 9, e001935.		38
16	Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist, 2021, 26, 514-522.	3.7	18
17	Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. , 2021, 9, e002007.		36
18	Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors. Oncologist, 2021, 26, e898-e901.	3.7	12

#	ARTICLE	IF	CITATIONS
19	Patients with steroid-refractory toxicity following immune checkpoint inhibitors: Frequent hospitalizations and long duration of illness.. Journal of Clinical Oncology, 2021, 39, 2655-2655.	1.6	0
20	Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center. Oncologist, 2021, 26, e1427-e1433.	3.7	11
21	What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications. Current Treatment Options in Oncology, 2021, 22, 53.	3.0	2
22	Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors. Journal of Immunotherapy and Precision Oncology, 2021, 4, 35-44.	1.4	4
23	Impact of multidisciplinary severe immunotherapy complication service on outcomes for cancer patients receiving immune checkpoint inhibition.. Journal of Clinical Oncology, 2021, 39, 2654-2654.	1.6	0
24	Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19. Oncologist, 2021, 26, 685-693.	3.7	3
25	Pericardial disease in patients treated with immune checkpoint inhibitors. , 2021, 9, e002771.		33
26	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.		87
27	Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data. , 2021, 9, e002896.		20
28	Immune checkpoint inhibitorâ€‘induced thyroiditis is a risk factor for acute and chronic kidney dysfunction. Nephrology Dialysis Transplantation, 2021, 37, 187-189.	0.7	2
29	Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. , 2021, 9, e002886.		9
30	Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors. Nephrology Dialysis Transplantation, 2021, 36, 2241-2247.	0.7	33
31	Immune checkpoint inhibitors for cancer and venous thromboembolic events. European Journal of Cancer, 2021, 158, 99-110.	2.8	35
32	814â€‘...Cutaneous immune-related adverse events are protective of mortality in patients treated with anti-PD1 and anti-PDL1 therapy in a multi-institutional cohort study. , 2021, 9, A850-A851.		0
33	804â€‘...Real-world incidence and impact of pneumonitis in lung cancer patients treated with immune checkpoint inhibitors. , 2021, 9, A841-A841.		0
34	Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study. Journal of the American Academy of Dermatology, 2020, 82, 743-746.	1.2	9
35	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist, 2020, 25, e398-e404.	3.7	10
36	Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation, 2020, 142, 2299-2311.	1.6	282

#	ARTICLE	IF	CITATIONS
37	Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors. <i>Kidney International Reports</i> , 2020, 5, 1700-1705.	0.8	47
38	Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis. , 2020, 8, e001329.		11
39	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020, 395, 1907-1918.	13.7	1,395
40	Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Circulation</i> , 2020, 141, 2031-2034.	1.6	142
41	Diagnostic evaluation of immune checkpoint inhibitor (CPI) colitis: The role of CT scan.. <i>Journal of Clinical Oncology</i> , 2020, 38, 821-821.	1.6	0
42	Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control. <i>Cancer Medicine</i> , 2019, 8, 4986-4999.	2.8	27
43	The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1692-1700.	4.5	193
44	Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. <i>American Journal of Hematology</i> , 2019, 94, 563-574.	4.1	51
45	Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System. <i>JAMA Oncology</i> , 2019, 5, 358.	7.1	48
46	Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. <i>European Journal of Endocrinology</i> , 2019, 181, 211-219.	3.7	116
47	Factors associated with severity of immune checkpoint inhibitor gastroenterocolitis requiring hospitalization in melanoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 81-81.	1.6	0
48	Flu vaccination rate of patients with severe immune-related adverse events.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18234-e18234.	1.6	1
49	Clinical outcomes of patients with stage IV cancer receiving immune checkpoint inhibitors in the inpatient setting.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6634-6634.	1.6	2
50	Clinical Features of Immune Checkpoint Inhibitor-Associated Autoimmune Hemolytic Anemia: A Series of 14 Cases. <i>Blood</i> , 2018, 132, 1037-1037.	1.4	1